Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that the first participant has been dosed in the Phase 1 study of the Company’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2). This Phase 1 study is being conducted by the US National Institutes of Health (NIH) under its own Investigational New Drug (IND) application.

Read more

Photo by Martin Sanchez on Unsplash

Nicole Verbeeck

Nicole Verbeeck

Nicole Verbeeck is Founder and Editor-in-Chief of Moonshot for Life, covering global health progress. She is also founder of Juneau Cayenne, a creative design, content and technology lab crafting innovative storytelling experiences for clients in healthcare and life sciences worldwide and she is a healthy food chef focusing on prevention of disease.

Share this with your network?

It might help your network to realize the next step of progress!